Trump admin revamps 340B pilot to rebate model
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- The Trump administration revised a pilot for the 340B Drug Pricing Program, allowing pharmaceutical companies to provide "timely" rebates to certain hospitals and clinics rather than upfront discounts on purchased medicines.
- The revised pilot takes effect Jan. 1, 2027 and specifically targets drugs and pharmaceutical companies involved in the first two rounds of the Medicare Drug Price Negotiation Program.
- Tom Engels, who heads the Health Resources and Services Administration, said the revision "helps modernize program oversight by improving visibility into 340B transactions while helping preserve the program's long-term sustainability."
- Hospitals are angered by the shift, which the source describes as a controversial move that "may transform a key tenet" of the federal drug discount program that has historically relied on upfront pricing reductions.
- The 340B Drug Pricing Program is a federal drug discount program that requires drugmakers to offer upfront discounts to safety-net hospitals and clinics serving low-income patients — a structural feature the rebate pilot now alters.
Why it matters: The revision inverts a core design of the 340B program: instead of receiving upfront discounts, participating hospitals would now pay full price and wait for rebates, shifting working-capital risk onto safety-net providers. By targeting drugs already subject to Medicare price negotiations, the pilot also intensifies pricing pressure on those specific products while giving drugmakers cash-flow flexibility.
